Silo Pharma buys software IP with 165K shares

Silo Pharma, Inc. (SILO) entered into an asset purchase agreement with Parkview Consulting LLC on August 18, 2026 to acquire certain software, technology, domain names and related intellectual property.

Rhea-AI Filing Summary

Silo Pharma, Inc. (SILO) entered into an asset purchase agreement with Parkview Consulting LLC on August 18, 2026 to acquire certain software, technology, domain names and related intellectual property. In exchange for these assets, Silo Pharma issued 165,000 shares of its common stock to the seller.

The issued shares are subject to a lock-up period starting on the agreement’s effective date and ending on the earlier of 12 months after that date, a defined Change in Control, or written consent of Silo Pharma. During this period, the seller is restricted from transferring or hedging the shares without Silo Pharma’s prior written consent. The agreement includes customary representations, warranties and covenants, and the seller agreed to indemnify Silo Pharma for specified misrepresentations, breaches, third‑party infringement issues and certain misconduct.

Filing Explained

The asset payment was completed through an unregistered common-stock issuance, and the seller’s manager is also a company strategic advisor.

The filing separately reports the share payment as an unregistered sale under Section 4(a)(2); because the consideration was common stock, the completed transaction changes the ownership structure by issuing equity to the asset seller.

Form 8-K reports specified material events within four business days; here, Item 3.02 records the offer and sale of the shares as unregistered.

The seller’s sole member and manager, Corwin Yu, is also identified as the company’s lead strategic advisor on its Cryptocurrency Advisory Board.

8-K Event Classification

3 items: 1.01, 3.02, 9.01

3 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 3.02 Unregistered Sales of Equity Securities Securities

The company sold equity securities in a private placement or other unregistered transaction.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Shares issued to seller: 165,000 shares Lock-up duration: 12 months Agreement date: August 18, 2026 +1 more

4 metrics

Shares issued to seller 165,000 shares Common stock issued to Parkview Consulting LLC as consideration for the purchased assets

Lock-up duration 12 months Maximum lock-up period after the agreement’s effective date, subject to earlier events

Agreement date August 18, 2026 Date Silo Pharma entered into the asset purchase agreement with Parkview Consulting LLC

Exhibit number 10.1 Asset Purchase Agreement between Silo Pharma and Parkview Consulting LLC listed as an exhibit

Key Terms

asset purchase agreement, lock-up period, Change in Control, indemnify, +1 more

5 terms

asset purchase agreement financial

"entered into an asset purchase agreement with Parkview Consulting LLC"

An asset purchase agreement is a legal contract in which a buyer agrees to buy specific assets and contracts of a business rather than buying the company’s stock or ownership. It matters to investors because it determines exactly what is being bought and what liabilities stay behind — like buying the furniture and equipment from a store but not the building or past debts — which affects the deal’s value, taxes and future risk exposure.

lock-up period financial

"The Shares are subject to a lock-up period beginning on the effective date"

A lock-up period is a fixed time after a stock offering during which company insiders and early investors are legally barred from selling their shares. It matters because when that restriction expires a large block of previously locked-up shares can enter the market at once, potentially lowering the stock price or spiking trading volume—like opening a floodgate—so investors monitor these dates to anticipate price moves and manage risk.

Change in Control financial

"ending on the earlier of (i) twelve (12) months after such date, (ii) a Change in Control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

indemnify financial

"the Seller agreed to indemnify the Company for any misrepresentation or breach"

To indemnify means to promise to cover or reimburse someone for losses, costs, or legal claims that arise from a specified action or event. For investors, indemnification shifts potential financial risk—like a safety net or warranty—so a party that agrees to indemnify protects others from unexpected liabilities, which can affect a company’s future expenses, deal terms, and perceived investment risk.

Section 4(a)(2) regulatory

"offer and sale to the Seller of the Shares was made in reliance upon Section 4(a)(2)"

Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Silo Pharma (SILO) announce on August 18, 2026?

Silo Pharma entered into an asset purchase agreement with Parkview Consulting LLC to acquire software, technology, domain names, and related intellectual property. Consideration was paid entirely in Silo Pharma common stock.

How many shares did Silo Pharma (SILO) issue for the acquired assets?

Silo Pharma issued 165,000 shares of its common stock to Parkview Consulting LLC as consideration for the purchased software, technology, domain names, and related intellectual property under the asset purchase agreement.

What are the lock-up terms on the 165,000 Silo Pharma (SILO) shares?

The 165,000 shares are subject to a lock-up period starting on the agreement’s effective date and ending on the earlier of 12 months after that date, a Change in Control, or Silo Pharma’s written consent, limiting transfers or hedging without prior approval.

Who is the seller in Silo Pharma’s (SILO) asset purchase and what is their role?

The seller is Parkview Consulting LLC, whose sole member and manager, Corwin Yu, currently serves as the lead strategic advisor on Silo Pharma’s Cryptocurrency Advisory Board, linking the seller to an advisory role at the company.

Under what securities law exemption were Silo Pharma (SILO) shares issued to the seller?

The offer and sale of the 165,000 shares to Parkview Consulting LLC were made in reliance on Section 4(a)(2) of the Securities Act of 1933 and related rules, covering certain private, non-public offerings.

What indemnification obligations does the seller have to Silo Pharma (SILO)?

Parkview Consulting LLC agreed to indemnify Silo Pharma for misrepresentations or breaches under the agreement, infringement of any third‑party rights by the software, and acts of gross negligence, fraud, or intentional misconduct by the seller.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/19/2026 - 05:17 PM Accepted by SEC EDGAR 08/19/2026 - 05:17 PM Learn about SEC filing dates

false 0001514183 0001514183 2026-08-18 2026-08-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 18, 2026

Silo Pharma, Inc.

(Exact name of registrant as specified in its charter)

Nevada		001-41512		27-3046338
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

677 N. Washington Boulevard Sarasota, FL		34236
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (718) 400-9031

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Rule 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of exchange on which registered
Common Stock, par value $0.0001 per share		SILO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On August 18, 2026, Silo Pharma, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Parkview Consulting LLC (the “Seller”). Pursuant to the Agreement, the Seller agreed to sell, and the Company agreed to purchase, certain software, technology, domain names, and related intellectual property (the “Purchased Assets”). Corwin Yu, the sole member and manager of the Seller, currently serves as the lead strategic advisor on the Company’s Cryptocurrency Advisory Board.

In consideration for the Purchased Assets, the Company issued to the Seller, 165,000 shares of its common stock, par value $0.0001 per share (the “Shares”). The Shares are subject to a lock-up period beginning on the effective date of the Agreement and ending on the earlier of (i) twelve (12) months after such date, (ii) a Change in Control, as defined in the Agreement, or (iii) written consent of the Company (the “Lock Up Period”). During the Lock Up Period, the Seller may not, without the Company’s prior written consent, directly or indirectly, offer, sell, contract to sell, hedge, pledge, grant any option, right or warrant to purchase, or otherwise transfer or dispose of any of the Shares, or enter into any swap or other agreement or transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of any of the Shares.

The Agreement contains certain representations, warranties and covenants of the parties that are customary for agreements of its type. In addition, the Seller agreed to indemnify the Company for any misrepresentation or breach under the Agreement, infringement of any third-party right by any portion of the software and any acts of gross negligence, fraud or intentional misconduct by the Seller.

The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 3.02 Unregistered Sales of Equity Securities.

The information set forth under Item 1.01 is incorporated herein by reference.

The offer and sale to the Seller of the Shares was made in reliance upon Section 4(a)(2) under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
10.1*		Asset Purchase Agreement, dated August 18, 2026, between the Company and Parkview Consulting LLC.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* The schedules (and similar attachments) to this exhibit have been omitted from this filing pursuant to Item 601(b)(10) of Regulation S-K. The Company agrees to furnish a supplemental copy of any omitted schedule (or similar attachment) to the Securities and Exchange Commission upon request.

-1-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SILO PHARMA, INC.
Date: August 19, 2026	By:	/s/ Eric Weisblum
		Eric Weisblum
		Chief Executive Officer

-2-

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

• EX-10.1 ASSET PURCHASE AGREEMENT, DATED AUGUST 18, 2026, BETWEEN THE COMPANY AND PARKVIE 32.4 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB